NL-OMON41641已完成2 期
Pertuzumab + trastuzumab (PH) versus PH plus metronomic chemotherapy (PHM) in the elderly HER2+ metastatic breast cancer population who may continue on T-DM1 alone following disease progression while on PH / PHM: an open-label multicentre randomized phase II selection trial of the EORTC Elderly Task Force and Breast Cancer Group - Elderly met BC: PH vs PHM followed by T-DM1
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- EORTC
- 入组人数
- 7
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •-Female or male patients with histologically proven HER-2 positive (IHC 3+ or or
- •HER-2 gene amplification by in situ hybridization [FISH, SISH].
- •-Patientsmust have measurable (RECIST v. 1.1) or evaluable disease
- •-Performance status (PS) 0-3 (WHO)
- •-Age >= 70 years of age, or >= 60 years old with required number of
- •dependencies as described below :
- •65 - 69 in combination with functional restriction defined as limitation
- •in at least 2 of 8 iADL or 1 of 6 ADL or Charlson comorbidity score > 2
- •60 - 64 in combination with functional restrictions defined as
- •limitation in at least 3 of 8 iADL 2 of 6 ADL or Charlson comorbidity score
- •-Life expectancy of more than 12 weeks
- •-Previous adjuvant chemotherapy/anti HER-2 therapy after surgery is
- •allowed, given that the time interval from end of previous treatment to
- •initiation of treatment for metastatic disease is >=6 months.
- •-Up to one line of anti-HER therapy (trastuzumab or lapatinib) is allowed
- •in combination with hormone therapy for hormone sensitive metastatic
- •breast cancer.
- •-Adequate organ function, evidenced by the following laboratory results
- •within 3 weeks prior to randomization: (patients with a buffer range
- •from the normal values of +/- 5% for hematology and +/- 10% for
- •biochemistry [with the EXCEPTION of Glomerular Filtration Rate] are
- •acceptable)
- •-Absolute neutrophil count > 1500 cells/mm3
- •-Platelet count > 100,000 cells/mm3
- •-Hemoglobin > 8.5 g/dL
- •-Total bilirubin <= 1.5 upper limit of normal (ULN)
- •-SGOT (AST), SGPT (ALT), and alkaline phosphatase <= 2.5× ULN (for
- •alkaline phosphatase limit applies in the absence of bone metastases)
- •-Glomerular Filtration Rate (GFR) >= 30 ml/min according to MDRD
- •formula or Cockcroft and Gault Formula
- •-Absence of any psychological, familial, sociological or geographical
- •condition potentially hampering compliance with the study protocol and
- •follow-up schedule; those conditions should be discussed with the
- •patient before registration in the trial
- •-Before patient randomization, written informed consent must be given
- •according to ICH/GCP, and national/local regulations.
- •-Newly diagnosed or recurrent (after surgery) stage IV disease
- •(TNM/AJCC v.7).
排除标准
- •-Current symptomatic brain metastases.
- •-Prior chemotherapy for metastatic disease.
- •-Prior treatment with pertuzumab.
- •-History of exposure to the following cumulative doses of anthracyclines:
- •Doxorubicin or liposomal doxorubicin > 360 mg/m2
- •Epirubicin > 720 mg/m2
- •Mitoxantrone > 120 mg/m2
- •Idarubicin > 90 mg/m2
- •If another anthracycline or more than 1 anthracycline has been used,
- •then the cumulative dose must not exceed the equivalent of 360 mg/m2
- •of doxorubicin.
- •-History of palliative radiotherapy within 14 days of /prior to randomization.
- •-History of other malignancy within the last 5 years, except for carcinoma in situ of the cervix or basal cell or spinocellular carcinoma of the skin.
- •-Current uncontrolled hypertension (persistent systolic > 180 mmHg
- •and/or diastolic > 100 mmHg) (with or without medication).
- •-LVEF below 50%.
- •-History of significant cardiac disease defined as:
- •Symptomatic CHF (NYHA classes II-IV, see Appendix C)
- •High-risk uncontrolled arrhythmias, i.e. atrial tachycardia with a heart
- •rate > 100/min at rest, significant ventricular arrhythmia (ventricular
- •tachycardia) or higher-grade AV-block (second degree AV-block Type 2
- •[Mobitz 2] or third degree AV-block)
- •History of myocardial infarction within 6 months prior to randomization
- •Clinically significant valvular heart disease
- •angina pectoris requiring anti-angina treatment
- •-Peripheral neuropathy of Grade >=3 per NCI CTCAE version 4.0.
- •current severe, uncontrolled systemic disease (e.g., clinically significant
- •cardiovascular, pulmonary, or metabolic disease; wound healing
- •disorders; ulcers; or bone fractures, known infection with HIV, active
- •hepatitis B and/or hepatitis C virus)
- •-Major surgical procedure or significant traumatic injury within 28 days
- •prior to randomization or anticipation of the need for major surgery
- •during the course of study treatment.
- •-History of receiving any investigational treatment within 28 days of
- •randomization.
- •-History of intolerance (including Grade 3-4 infusion reaction) to
- •trastuzumab.
- •-Unwillingness or inability to comply with the requirements of the
- •protocol as assessed by the investigator.
研究者
相似试验
进行中（未招募）
1 期
A trial of Pertuzumab and Herceptin versus Pertuzumab and Herceptin and metronomic chemotherapy in elderly patients with Her2 positive metastatic breast cancer, with the option to receive TDM-1 at disease progressioewly diagnosed or recurrent (after surgery) stage IV (TNM/AJCC v.7) HER-2 positive (IHC 3+ or or HER-2 gene amplification by in situ hybridization) invasive breast cancerMedDRA version: 18.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2011-006342-32-NLEORTC80
进行中（未招募）
1 期
A trial of Pertuzumab and Herceptin versus Pertuzumab and Herceptin and metronomic chemotherapy in elderly patients with Her2 positive metastatic breast cancer, with the option to receive TDM-1 at disease progressioEUCTR2011-006342-32-ITEORTC80
进行中（未招募）
1 期
A trial of Pertuzumab and Herceptin versus Pertuzumab and Herceptin and metronomic chemotherapy in elderly patients with Her2 positive metastatic breast cancer, with the option to receive TDM-1 at disease progressioewly diagnosed or recurrent (after surgery) stage IV (TNM/AJCC v.7) HER-2 positive (IHC 3+ or or HER-2 gene amplification by in situ hybridization) invasive breast cancerMedDRA version: 20.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2011-006342-32-SEEORTC80
进行中（未招募）
1 期
A trial of Pertuzumab and Herceptin versus Pertuzumab and Herceptin and metronomic chemotherapy in elderly patients with Her2 positive metastatic breast cancer, with the option to receive TDM-1 at disease progressioewly diagnosed or recurrent (after surgery) stage IV (TNM/AJCC v.7) Histologically proven HER-2 positive (IHC 3+ or or HER-2 gene amplification by in situ hybridization) invasive breast cancerMedDRA version: 20.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2011-006342-32-GBEORTC80
进行中（未招募）
1 期
A trial of Pertuzumab and Herceptin versus Pertuzumab and Herceptin and metronomic chemotherapy in elderly patients with Her2 positive metastatic breast cancer, with the option to receive TDM-1 at disease progressioewly diagnosed or recurrent (after surgery) stage IV (TNM/AJCC v.7) HER-2 positive (IHC 3+ or or HER-2 gene amplification by in situ hybridization) invasive breast cancerMedDRA version: 20.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2011-006342-32-BEEORTC80